OmniAb's Milestone Engine Finally Put Up Real Numbers — and the Market Paid Up
Q2 revenue tripled, xPloration sold its first instruments, and guidance went up again; the stock's +195% move says the re-rating has begun.
OABI · Earnings Call · 2026-08-06
A Quarter That Put Numbers on the Narrative
OmniAb has spent the better part of two years telling investors the same story: the platform's real value sits in a deep pipeline of partner programs whose downstream milestones and royalties would eventually convert into meaningful, recurring revenue. For a long time the numbers didn't cooperate — revenue drifted from its $17M peak in Q1 2023 down to a low-single-digit run-rate through 2024–2025. This quarter the arc finally bent. Q2 2026 revenue came in at $13.4M versus $3.9M a year ago, and management raised full-year 2026 revenue guidance to $32–36M. Kurt Gustafson put it plainly: “We've increased the range for 2026 total revenue to $32 million to $36 million.” — Kurt Gustafson, Chief Financial Officer · 2026-08-06 The tape responded violently. After rising roughly 71% across the nine weeks into the print, the stock added about 121% in the two weeks around the report — a +195% move over the trailing 90 days. For a $374M market cap, this is a re-rating, not a wobble. The fundamentals are trying to catch up: Q1 2026 revenue printed $14M on +247% y/y growth, and with Q2's $13.4M, the first half already exceeds full-year 2025's total. Milestone timing — the old excuse for lumpiness — has become the source of the acceleration.The Pipeline Is Doing the Heavy Lifting
Matt Foehr's prepared remarks leaned hard on clinical advancement: “We're excited to report that the programs derived from our differentiated discovery technologies continue to move into the clinic and to make progress through later-stage clinical development.” — Matthew Foehr, Chief Executive Officer · 2026-08-06 The clinical program count stands at 34, and two programs jumped straight from Phase I to Phase III in the quarter — J&J's Ramantamig trispecific for multiple myeloma and Merck KGaA's CEACAM5 ADC for colorectal cancer. Those are the events that trigger milestone payments, and OmniAb holds $340M of contracted milestones against its active clinical programs alone. This is the quarter the milestone revenue thesis stopped being theoretical. There's a timing wrinkle worth flagging: receivables swelled to roughly 88% of quarterly revenue because, as Gustafson noted, “certain milestones were achieved in the second quarter but not yet paid.” The cash will presumably land, but it is a reminder that reported revenue and cash flow won't always move in lockstep.xPloration Finally Ships
The biggest company-specific news is that the xPloration platform — the high-throughput single-B-cell screening instrument pitched since mid-2025 — has begun to sell. “We achieved an important milestone within Q2 with the sale of 2 instruments, while strong commercial interest continues to expand our sales pipeline.” — Matthew Foehr, Chief Executive Officer · 2026-08-06 That brings the fielded base to 4 units. The contrast with prior quarters is stark. On the 2026-03-05 call, Matt Foehr described the base tersely: “So a quick answer to the first part of the question is 2, instruments deployed as of the end of 2025.” — Matthew Foehr, Chief Executive Officer · 2026-03-05 Now deployment has turned into repeat sales, and the instrument's razor-and-razorblade economics — proprietary consumables, software subscriptions, maintenance contracts — are the real prize. Part of the confidence on the commercial side: OmniAb just hired a life-sciences-tools veteran as COO, Amechi Nwachuku, whom Foehr highlighted as “an established and highly experienced global executive to help lead and grow the business.” — Matthew Foehr, Chief Executive Officer · 2026-08-06 The Amechi keyword is brand new to the company's trajectory this quarter — a signal the board is serious about the instrument business.Partners, Economics, and the Cost Engine
The partner base grew again to 110, headlined by two new licenses: EnRosa Therapeutics and, more notably, argenx, a global immunology leader. Foehr pointed to the widening ecosystem of partners as evidence of momentum, noting “the big players are taking bigger swings.” Meanwhile, the cost discipline promised for years is visible in the numbers. R&D fell 24% y/y and SG&A fell 16% y/y; net loss improved to $5.9M from $15.9M. R&D spend, at $10M in Q1 2026, is the lowest in years. Kurt framed it as the payoff of scale. The counterpoint to optimism is the burn: cash is guided to $37–41M at year-end, implying the company still consumes roughly $15M of cash this year despite the revenue spike. And a sobering detail: H1 revenue of $27.8M sits at the high end of the $32–36M guidance, meaning the back half is guided to a sharp deceleration in milestone flow. That is inherent lumpiness, not deterioration — but it keeps the model hostage to individual program timetables.The last genuinely interesting contrast is financial posture. As recently as the 2025-11-04 call, Gustafson explained the late-2025 equity raise as prudent timing: “We took a look at our forecast and decided it was the right time to sort of bolster the balance sheet.” — Kurt Gustafson, Chief Financial Officer · 2025-11-04 Two quarters later, cash rose on operations alone. And the pipeline's downstream option value — including IMVT 1402, where Immunovant this week confirmed progress across all six announced indications — gives this story a multi-trigger path. The market is finally pricing that in. Whether the back half delivers the milestones to sustain the re-rating is the open question — but the direction of travel has clearly changed.While we are still in a period where revenue is largely driven by milestones, which can be highly variable in any given quarter, our portfolio of partner programs has continued to grow and advance… we are beginning to see the benefits of our business model take hold.